Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Ejhaem
|
October 17, 2024
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol
Neil D Palmisiano, Ju-Whei Lee, David F Claxton, et al.
Leukemia
|
February 15, 2025
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia
Sameem M Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, et al.
Haematologica
|
July 24, 2025
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Samuel J Yates, Julian J Weiss, Abigail Sneider, et al.
Blood Advances
|
November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Nature Chemistry
|
November 24, 2017
Single-crystal-to-single-crystal intercalation of a low-bandgap superatomic crystal
Evan S O'Brien, M Tuan Trinh, Rose L Kann, et al.
Leukemia & Lymphoma
|
September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
Muhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
Science (New York, N.Y.)
|
August 8, 2024
Toward liquid cell quantum sensing: Ytterbium complexes with ultranarrow absorption
Ashley J Shin, Changling Zhao, Yi Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial
Nitin Jain, Emily Curran, Neil M Iyengar, et al.
The New England Journal of Medicine
|
July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
Mark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Ejhaem
|
October 17, 2024
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol
Neil D Palmisiano, Ju-Whei Lee, David F Claxton, et al.
Leukemia
|
February 15, 2025
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia
Sameem M Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, et al.
Haematologica
|
July 24, 2025
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Samuel J Yates, Julian J Weiss, Abigail Sneider, et al.
Blood Advances
|
November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Nature Chemistry
|
November 24, 2017
Single-crystal-to-single-crystal intercalation of a low-bandgap superatomic crystal
Evan S O'Brien, M Tuan Trinh, Rose L Kann, et al.
Leukemia & Lymphoma
|
September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
Muhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
Science (New York, N.Y.)
|
August 8, 2024
Toward liquid cell quantum sensing: Ytterbium complexes with ultranarrow absorption
Ashley J Shin, Changling Zhao, Yi Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial
Nitin Jain, Emily Curran, Neil M Iyengar, et al.
The New England Journal of Medicine
|
July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
Mark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.
Page
of 5